vs
ENBRIDGE INC（ENB）与美敦力（MDT）财务数据对比。点击上方公司名可切换其他公司
美敦力的季度营收约是ENBRIDGE INC的1.6倍（$9.0B vs $5.7B），ENBRIDGE INC净利率更高（26.2% vs 15.3%，领先10.9%），美敦力同比增速更快（6.6% vs 5.3%），ENBRIDGE INC自由现金流更多（$2.4B vs $457.0M），过去两年ENBRIDGE INC的营收复合增速更高（7.6% vs 5.3%）
加拿大恩布里奇公司（Enbridge Inc.）是总部位于阿尔伯塔省卡尔加里的跨国能源管道企业，在加拿大、美国运营管网输送原油、天然气及天然气液，同时布局可再生能源业务。其管网是北美最长、全球规模最大的原油出口管网，拥有近2.9万公里原油管道及超3.83万公里天然气管道。
美敦力是全球知名的医疗设备企业，法定及行政总部位于爱尔兰，运营总部设在美国明尼苏达州明尼阿波利斯。2015年集团收购爱尔兰企业柯惠后将注册地迁至爱尔兰，目前业务覆盖超150个国家，员工逾9万名，专注于研发生产各类医疗技术产品及治疗解决方案。
ENB vs MDT — 直观对比
营收规模更大
MDT
是对方的1.6倍
$5.7B
营收增速更快
MDT
高出1.3%
5.3%
净利率更高
ENB
高出10.9%
15.3%
自由现金流更多
ENB
多$1.9B
$457.0M
两年增速更快
ENB
近两年复合增速
5.3%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $5.7B | $9.0B |
| 净利润 | $1.5B | $1.4B |
| 毛利率 | — | 65.8% |
| 营业利润率 | 34.7% | 18.8% |
| 净利率 | 26.2% | 15.3% |
| 营收同比 | 5.3% | 6.6% |
| 净利润同比 | 246.2% | 8.2% |
| 每股收益（稀释后） | — | $1.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ENBMDT
| Q4 25 | $5.7B | $9.0B | ||
| Q3 25 | $4.5B | $8.6B | ||
| Q2 25 | $4.8B | $8.9B | ||
| Q1 25 | $6.4B | $8.3B | ||
| Q4 24 | $5.4B | $8.4B | ||
| Q3 24 | $4.2B | $7.9B | ||
| Q2 24 | $4.3B | $8.6B | ||
| Q1 24 | $4.9B | $8.1B |
净利润ENBMDT
| Q4 25 | $1.5B | $1.4B | ||
| Q3 25 | $575.2M | $1.0B | ||
| Q2 25 | $1.7B | $1.1B | ||
| Q1 25 | $1.7B | $1.3B | ||
| Q4 24 | $434.4M | $1.3B | ||
| Q3 24 | $1.0B | $1.0B | ||
| Q2 24 | $1.4B | $654.0M | ||
| Q1 24 | $1.1B | $1.3B |
毛利率ENBMDT
| Q4 25 | — | 65.8% | ||
| Q3 25 | — | 65.0% | ||
| Q2 25 | — | 64.8% | ||
| Q1 25 | — | 66.5% | ||
| Q4 24 | — | 64.9% | ||
| Q3 24 | — | 65.1% | ||
| Q2 24 | 7.5% | 64.5% | ||
| Q1 24 | 26.2% | 65.6% |
营业利润率ENBMDT
| Q4 25 | 34.7% | 18.8% | ||
| Q3 25 | 36.9% | 16.8% | ||
| Q2 25 | 35.1% | 16.1% | ||
| Q1 25 | 41.7% | 19.9% | ||
| Q4 24 | 32.8% | 19.0% | ||
| Q3 24 | 38.7% | 16.1% | ||
| Q2 24 | 38.3% | 12.3% | ||
| Q1 24 | 40.0% | 18.3% |
净利率ENBMDT
| Q4 25 | 26.2% | 15.3% | ||
| Q3 25 | 12.8% | 12.1% | ||
| Q2 25 | 34.9% | 11.8% | ||
| Q1 25 | 26.8% | 15.6% | ||
| Q4 24 | 8.0% | 15.1% | ||
| Q3 24 | 24.3% | 13.2% | ||
| Q2 24 | 32.8% | 7.6% | ||
| Q1 24 | 22.3% | 16.3% |
每股收益（稀释后）ENBMDT
| Q4 25 | — | $1.07 | ||
| Q3 25 | — | $0.81 | ||
| Q2 25 | — | $0.81 | ||
| Q1 25 | — | $1.01 | ||
| Q4 24 | — | $0.99 | ||
| Q3 24 | — | $0.80 | ||
| Q2 24 | — | $0.50 | ||
| Q1 24 | — | $0.99 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $798.6M | $8.3B |
| 总债务越低越好 | $72.2B | $27.7B |
| 股东权益账面价值 | $45.5B | $48.7B |
| 总资产 | $159.5B | $91.3B |
| 负债/权益比越低杠杆越低 | 1.59× | 0.57× |
8季度趋势，按日历期对齐
现金及短期投资ENBMDT
| Q4 25 | $798.6M | $8.3B | ||
| Q3 25 | $1.0B | $8.1B | ||
| Q2 25 | $878.2M | $9.0B | ||
| Q1 25 | $1.5B | $7.9B | ||
| Q4 24 | $1.3B | $8.0B | ||
| Q3 24 | $1.4B | $7.8B | ||
| Q2 24 | $2.6B | $8.0B | ||
| Q1 24 | $886.2M | $8.3B |
总债务ENBMDT
| Q4 25 | $72.2B | $27.7B | ||
| Q3 25 | $73.4B | $26.2B | ||
| Q2 25 | $70.8B | $25.6B | ||
| Q1 25 | $70.9B | $24.0B | ||
| Q4 24 | $68.2B | $24.6B | ||
| Q3 24 | $63.7B | $26.3B | ||
| Q2 24 | $62.2B | $23.9B | ||
| Q1 24 | $59.4B | $24.2B |
股东权益ENBMDT
| Q4 25 | $45.5B | $48.7B | ||
| Q3 25 | $47.6B | $47.9B | ||
| Q2 25 | $47.8B | $48.0B | ||
| Q1 25 | $49.8B | $49.4B | ||
| Q4 24 | $48.1B | $48.5B | ||
| Q3 24 | $48.0B | $47.9B | ||
| Q2 24 | $49.1B | $50.2B | ||
| Q1 24 | $46.9B | $51.8B |
总资产ENBMDT
| Q4 25 | $159.5B | $91.3B | ||
| Q3 25 | $158.4B | $91.0B | ||
| Q2 25 | $154.5B | $91.7B | ||
| Q1 25 | $160.6B | $90.0B | ||
| Q4 24 | $159.9B | $90.0B | ||
| Q3 24 | $150.2B | $89.7B | ||
| Q2 24 | $146.9B | $90.0B | ||
| Q1 24 | $139.2B | $90.8B |
负债/权益比ENBMDT
| Q4 25 | 1.59× | 0.57× | ||
| Q3 25 | 1.54× | 0.55× | ||
| Q2 25 | 1.48× | 0.53× | ||
| Q1 25 | 1.42× | 0.49× | ||
| Q4 24 | 1.42× | 0.51× | ||
| Q3 24 | 1.33× | 0.55× | ||
| Q2 24 | 1.27× | 0.48× | ||
| Q1 24 | 1.27× | 0.47× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $9.0B | $925.0M |
| 自由现金流经营现金流 - 资本支出 | $2.4B | $457.0M |
| 自由现金流率自由现金流/营收 | 42.0% | 5.1% |
| 资本支出强度资本支出/营收 | 114.3% | 5.2% |
| 现金转化率经营现金流/净利润 | 5.96× | 0.67× |
| 过去12个月自由现金流最近4个季度 | — | $5.2B |
8季度趋势，按日历期对齐
经营现金流ENBMDT
| Q4 25 | $9.0B | $925.0M | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $2.5B | ||
| Q1 25 | $2.2B | $2.6B | ||
| Q4 24 | $9.2B | $958.0M | ||
| Q3 24 | — | $986.0M | ||
| Q2 24 | — | $2.8B | ||
| Q1 24 | $2.3B | $2.5B |
自由现金流ENBMDT
| Q4 25 | $2.4B | $457.0M | ||
| Q3 25 | — | $584.0M | ||
| Q2 25 | — | $2.1B | ||
| Q1 25 | $970.9M | $2.1B | ||
| Q4 24 | $4.3B | $554.0M | ||
| Q3 24 | — | $466.0M | ||
| Q2 24 | — | $2.4B | ||
| Q1 24 | $1.4B | $2.1B |
自由现金流率ENBMDT
| Q4 25 | 42.0% | 5.1% | ||
| Q3 25 | — | 6.8% | ||
| Q2 25 | — | 23.2% | ||
| Q1 25 | 15.1% | 25.3% | ||
| Q4 24 | 79.0% | 6.6% | ||
| Q3 24 | — | 5.9% | ||
| Q2 24 | — | 27.4% | ||
| Q1 24 | 29.0% | 26.3% |
资本支出强度ENBMDT
| Q4 25 | 114.3% | 5.2% | ||
| Q3 25 | — | 5.9% | ||
| Q2 25 | — | 5.1% | ||
| Q1 25 | 19.6% | 5.7% | ||
| Q4 24 | 90.1% | 4.8% | ||
| Q3 24 | — | 6.6% | ||
| Q2 24 | — | 5.0% | ||
| Q1 24 | 17.5% | 4.3% |
现金转化率ENBMDT
| Q4 25 | 5.96× | 0.67× | ||
| Q3 25 | — | 1.05× | ||
| Q2 25 | — | 2.39× | ||
| Q1 25 | 1.29× | 1.99× | ||
| Q4 24 | 21.18× | 0.75× | ||
| Q3 24 | — | 0.95× | ||
| Q2 24 | — | 4.25× | ||
| Q1 24 | 2.08× | 1.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ENB
暂无分部数据
MDT
| Cardiac Rhythm And Heart Failure Division | $1.8B | 20% |
| Surgical Endoscopy | $1.7B | 19% |
| Other | $1.3B | 14% |
| Structural Heart And Aortic Division | $956.0M | 11% |
| Diabetes Group | $757.0M | 8% |
| Specialty Therapies Division | $744.0M | 8% |
| Coronary And Peripheral Vascular Division | $655.0M | 7% |
| Neuromodulation Division | $520.0M | 6% |
| Acute Care Monitoring | $493.0M | 6% |
| IE | $35.0M | 0% |
